Study of Sivelestat Sodium in OPCABG

Condition(s) studied

Investigational drug(s) / intervention(s)

Sivelestat Sodium injection 2 h after OPCABG for 72 h: Sivelestat Sodium injection 2 h after OPCABG for 72 h

Saline (0.9% NaCl): Saline (0.9% NaCl) instead of Sivelestat

Study summary

The goal of this clinical trial is to learn if drug Sivelestat Sodium works to improve the prognosis of off-pump coronary artery bypass grafting (OPCABG) in adults. It will also learn about the safety of drug Sivelestat Sodium. The main questions it aims to answer are:

* Does drug Sivelestat Sodium have a protective effect on myocardial injury after OPCABG?
* Does Sivelestat Sodium exert a protective effect on myocardial inflammatory stress after OPCABG? Researchers will compare drug Sivelestat Sodium to a placebo (a look-alike substance that contains no drug) to see if drug Sivelestat Sodium works to protect myocardium following OPCABG.

Participants will:

* Accept drug Sivelestat Sodium injection or a placebo 2 h after OPCABG for 72 h.
* Undergo a series of blood tests and echocardiography examinations after the OPCABG.

Eligibility

Primary outcome measure(s)

• Myocardial injury — Day 3 after OPCABG
  Sivelestat Sodium exerts a protective effect on myocardial injury after OPCABG

Trial sites (1)

More Affiliated Hospital of Nantong University trials in China

Other trials for the same condition